Patents, Innovation and Access to New Pharmaceuticals

Henry Grabowski

No 02-28, Working Papers from Duke University, Department of Economics

Abstract: This paper considers the role of intellectual property rights in the development of and access to new pharmaceuticals. A number of studies have found patents are significantly more important to pharmaceutical firms in appropriating the benefits from innovation compared to other high tech industries. The reason for this is because the costs of drug innovation are very high while the costs of imitation are relatively low. Hence the industry is subject to significant free rider problems. The paper discusses the economics of the innovative process and considers how patent policies have evolved in response to these characteristics in several developed countries with research intensive drug firms. One area currently receiving policy attention is the effect of patents on the development of and access to new medicines in developing countries. The final section of the paper focuses on this issue and discusses the need for an orphan drug type program to stimulate more R&D on diseases specific to third world countries.

Date: 2002
New Economics Papers: this item is included in nep-com, nep-hea and nep-ind
References: Add references at CitEc
Citations: View citations in EconPapers (19)

Downloads: (external link)
http://www.econ.duke.edu/Papers/Abstracts02/abstract.02.28.html main text

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:duk:dukeec:02-28

Access Statistics for this paper

More papers in Working Papers from Duke University, Department of Economics Department of Economics Duke University 213 Social Sciences Building Box 90097 Durham, NC 27708-0097.
Bibliographic data for series maintained by Department of Economics Webmaster ().